APA

van Houdt I. S., Sluijter B. J. R., Moesbergen L. M., Vos W. M., de Gruijl T. D., Molenkamp B. G., van den Eertwegh A. J. M., Hooijberg E., van Leeuwen P. A. M., Meijer C. J. L. M. & Oudejans J. J. (20080703). Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. : International journal of cancer.

Chicago

van Houdt Inge S, Sluijter Berbel J R, Moesbergen Laura M, Vos Wim M, de Gruijl Tanja D, Molenkamp Barbara G, van den Eertwegh Alfons J M, Hooijberg Erik, van Leeuwen Paul A M, Meijer Chris J L M and Oudejans Joost J. 20080703. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. : International journal of cancer.

Harvard

van Houdt I. S., Sluijter B. J. R., Moesbergen L. M., Vos W. M., de Gruijl T. D., Molenkamp B. G., van den Eertwegh A. J. M., Hooijberg E., van Leeuwen P. A. M., Meijer C. J. L. M. and Oudejans J. J. (20080703). Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. : International journal of cancer.

MLA

van Houdt Inge S, Sluijter Berbel J R, Moesbergen Laura M, Vos Wim M, de Gruijl Tanja D, Molenkamp Barbara G, van den Eertwegh Alfons J M, Hooijberg Erik, van Leeuwen Paul A M, Meijer Chris J L M and Oudejans Joost J. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. : International journal of cancer. 20080703.